NCT00005797View on ClinicalTrials.gov

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 31, 1993

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Chronic Myeloproliferative DisordersLeukemiaMultiple Myeloma and Malignant Plasma Cell NeoplasmsMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

busulfan

administered on Day -7 through Day -4. The total dose is 12.8 mg/kg

DRUG

Cyclophosphamide

administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)

DRUG

VP-16

administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.

RADIATION

Fractionated Total Body Irradiation (FTBI)

FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00005797 - Bone Marrow Transplant in Treating Patients With Hematologic Cancers | Biotech Hunter | Biotech Hunter